SEC Form 4 filed by VP Corporate Controller Moller Andrew James

$CNMD
Biotechnology: Electromedical & Electrotherapeutic Apparatus
Health Care
Get the next $CNMD alert in real time by email
SEC FORM 4 SEC Form 4
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5
  
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
  
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Moller Andrew James

(Last) (First) (Middle)
C/O CONMED CORPORATION
11311 CONCEPT BOULEVARD

(Street)
LARGO FL 33773

(City) (State) (Zip)
2. Issuer Name and Ticker or Trading Symbol
CONMED Corp [ CNMD ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
Director 10% Owner
X Officer (give title below) Other (specify below)
VP Corporate Controller
3. Date of Earliest Transaction (Month/Day/Year)
01/27/2025
4. If Amendment, Date of Original Filed (Month/Day/Year)
6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Options To Purchase Common Stock $71.18 01/27/2025 A 5,000 (1) 01/27/2035 Common Stock 5,000 $0 5,000 D
Explanation of Responses:
1. The stock options were granted under the Company's 2018 Long-Term Incentive Plan and generally vest in equal amounts over a five year period
/s/ Thomas Fistek for Andrew James Moller by Power of Attorney 01/30/2025
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
Get the next $CNMD alert in real time by email

Chat with this insight

Save time and jump to the most important pieces.

Recent Analyst Ratings for
$CNMD

DatePrice TargetRatingAnalyst
2/6/2025$85.00 → $70.00Overweight → Neutral
Analyst
2/1/2024$119.00 → $129.00Buy
Needham
5/22/2023$140.00Buy
CL King
3/27/2023$124.00Sector Weight → Overweight
KeyBanc Capital Markets
3/21/2023$96.00Equal Weight
Wells Fargo
10/12/2022$85.00Hold
Jefferies
3/2/2022$155.00Neutral
BofA Securities
1/21/2022$158.00 → $150.00Buy
Needham
More analyst ratings

$CNMD
Press Releases

Fastest customizable press release news feed in the world

See more
  • CONMED Corporation Adds Mark Kaye to its Board of Directors

    CONMED Corporation (NYSE:CNMD) today announced that Mark Kaye will be joining its Board of Directors effective February 24th, 2025. "My fellow directors and I are extremely pleased to welcome Mark to the board," said Martha Goldberg Aronson, Chair of CONMED's Board of Directors. "Mark brings a wealth of experience to CONMED, including deep knowledge across finance, accounting, risk management, strategic planning, and operational efficiencies. He also brings a strong background and expertise in both corporate governance and healthcare. Mark's skills and insights will help guide CONMED's future direction." "Mark is an outstanding addition to our board," said Patrick Beyer, President and C

    $CNMD
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care
  • CONMED Corporation Announces Quarterly Cash Dividend

    CONMED Corporation (NYSE:CNMD) announced today that its Board of Directors declared a quarterly cash dividend of $0.20 per share on February 24, 2025, payable on April 4, 2025, to all shareholders of record as of March 14, 2025. About CONMED Corporation CONMED is a medical technology company that provides devices and equipment for surgical procedures. The Company's products are used by surgeons and other healthcare professionals in a variety of specialties, including orthopedics, general surgery, gynecology, thoracic surgery, and gastroenterology. For more information, visit www.conmed.com. Forward-Looking Statements This press release may contain forward-looking statements based on

    $CNMD
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care
  • CONMED Corporation Announces Fourth Quarter and Full-Year 2024 Financial Results

    CONMED Corporation (NYSE:CNMD) today announced financial results for the fourth quarter and full-year ended December 31, 2024. Fourth Quarter 2024 Highlights Sales of $345.9 million increased 5.8% year over year as reported and 6.0% in constant currency. Domestic revenue increased 6.8% year over year. International revenue increased 4.4% year over year as reported and 5.0% in constant currency. Diluted net earnings per share (GAAP) were $1.08 compared to diluted net earnings per share (GAAP) of $1.05 in the fourth quarter of 2023. Adjusted diluted net earnings per share(1) were $1.34, an increase of 26.4% compared to the fourth quarter of 2023. Full-Year 2024 Highlights

    $CNMD
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

$CNMD
Analyst Ratings

Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

See more

$CNMD
Insider Purchases

Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

See more

$CNMD
Insider Trading

Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

See more

$CNMD
SEC Filings

See more

$CNMD
Leadership Updates

Live Leadership Updates

See more
  • Beta Bionics Announces the Appointment of Martha Goldberg Aronson as Chair of Its Board of Directors

    CONCORD, Mass.--(BUSINESS WIRE)--Beta Bionics, Inc., a medical technology company focused on the design, development, and commercialization of the iLet® bionic pancreas system, today announced the appointment of Martha Goldberg Aronson as Chair of its Board of Directors, effective immediately. Ms. Aronson, who joined the Beta Bionics Board as a Director in February of 2020, succeeds Ed Damiano, President and Chief Executive Officer of Beta Bionics, who has served as Chair since inception of the company in 2015. Dr. Damiano will remain a member of the Board while continuing to serve in his roles as President and Chief Executive Officer of Beta Bionics. “On behalf of the Board, I am

    $CSII
    $MEI
    $CNMD
    Medical/Dental Instruments
    Health Care
    Electrical Products
    Technology

$CNMD
Financials

Live finance-specific insights

See more
  • CONMED Corporation Announces Quarterly Cash Dividend

    CONMED Corporation (NYSE:CNMD) announced today that its Board of Directors declared a quarterly cash dividend of $0.20 per share on February 24, 2025, payable on April 4, 2025, to all shareholders of record as of March 14, 2025. About CONMED Corporation CONMED is a medical technology company that provides devices and equipment for surgical procedures. The Company's products are used by surgeons and other healthcare professionals in a variety of specialties, including orthopedics, general surgery, gynecology, thoracic surgery, and gastroenterology. For more information, visit www.conmed.com. Forward-Looking Statements This press release may contain forward-looking statements based on

    $CNMD
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care
  • CONMED Corporation Announces Fourth Quarter and Full-Year 2024 Financial Results

    CONMED Corporation (NYSE:CNMD) today announced financial results for the fourth quarter and full-year ended December 31, 2024. Fourth Quarter 2024 Highlights Sales of $345.9 million increased 5.8% year over year as reported and 6.0% in constant currency. Domestic revenue increased 6.8% year over year. International revenue increased 4.4% year over year as reported and 5.0% in constant currency. Diluted net earnings per share (GAAP) were $1.08 compared to diluted net earnings per share (GAAP) of $1.05 in the fourth quarter of 2023. Adjusted diluted net earnings per share(1) were $1.34, an increase of 26.4% compared to the fourth quarter of 2023. Full-Year 2024 Highlights

    $CNMD
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care
  • CONMED Corporation to Announce Fourth Quarter 2024 Financial Results on February 5, 2025

    CONMED Corporation (NYSE:CNMD) today announced that it will report financial results for the fourth quarter 2024 after the market close on Wednesday, February 5, 2025. The Company's management will host a conference call at 4:30 p.m. ET that same day to discuss the results. To participate in the conference call via telephone, please click here to pre-register and obtain the dial-in number and passcode. This conference call will also be webcast and can be accessed from the "Investors" section of CONMED's website at www.conmed.com. The webcast replay of the call will be available at the same site approximately one hour after the end of the call. About CONMED Corporation CONMED is a me

    $CNMD
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

$CNMD
Large Ownership Changes

This live feed shows all institutional transactions in real time.

See more